|
Sino Biological
anti pd 1 antibody Anti Pd 1 Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/PD1+%2F+PDCD1+%2F+CD279+Blocking+Antibody/pmc06162236-131-0-5 Average 93 stars, based on 1 article reviews
anti pd 1 antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Merus Labs
anti-human pd1 ![]() Anti Human Pd1, supplied by Merus Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/anti+pd1+blocking+antibody/pmc06558289-21-0-3 Average 90 stars, based on 1 article reviews
anti-human pd1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Agenus Inc
blocking pd-1 monoclonal antibody ![]() Blocking Pd 1 Monoclonal Antibody, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/blocking+pd+1+monoclonal+antibody/pmc04277117-181-12-26 Average 90 stars, based on 1 article reviews
blocking pd-1 monoclonal antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Coherus Biosciences
pd-1 blocking antibodies loqtorzi ![]() Pd 1 Blocking Antibodies Loqtorzi, supplied by Coherus Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/pd+1+blocking+antibodies+loqtorzi/pm38409589-53-8-23 Average 90 stars, based on 1 article reviews
pd-1 blocking antibodies loqtorzi - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
pd-1 blocking antibody ![]() Pd 1 Blocking Antibody, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/pd+1+blocking+antibody/pmc07347689-37-31-36 Average 90 stars, based on 1 article reviews
pd-1 blocking antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Merck & Co
anti-pd-1 blocking antibodies ![]() Anti Pd 1 Blocking Antibodies, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/pembrolizumab+anti/pmc05483881-140-7-11 Average 90 stars, based on 1 article reviews
anti-pd-1 blocking antibodies - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
InvitroCue
anti-pd-1-blocking antibody ![]() Anti Pd 1 Blocking Antibody, supplied by InvitroCue, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/anti+pd+1+blocking+antibody/pmc11967763-300-23-28 Average 90 stars, based on 1 article reviews
anti-pd-1-blocking antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
BioExpress
blocking mab specific for murine pd-1 clone j43 antibody ![]() Blocking Mab Specific For Murine Pd 1 Clone J43 Antibody, supplied by BioExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/blocking+mab+specific+for+murine+pd+1+clone+j43+antibody/pm16900095-121-4-14 Average 90 stars, based on 1 article reviews
blocking mab specific for murine pd-1 clone j43 antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
blocking anti-pd-1 antibody ![]() Blocking Anti Pd 1 Antibody, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/blocking+anti+pd+1+antibody/pmc09975936-238-4-13 Average 90 stars, based on 1 article reviews
blocking anti-pd-1 antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Becton Dickinson
pd-1 blocking antibody ![]() Pd 1 Blocking Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/pd+1+blocking+antibody/pmc03989168-105-64-69 Average 90 stars, based on 1 article reviews
pd-1 blocking antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Ansell Healthcare
pd-1-blocking antibody ![]() Pd 1 Blocking Antibody, supplied by Ansell Healthcare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/pd+1+blocking+antibody/pm31962268-25-17-36 Average 90 stars, based on 1 article reviews
pd-1-blocking antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Federation of European Neuroscience Societies
ctla4 biochemical receptor ![]() Ctla4 Biochemical Receptor, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/antibodies+blocking+pd1/pd+1+blocking+antibodies/pm26807978-50-0-31 Average 90 stars, based on 1 article reviews
ctla4 biochemical receptor - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cell
Article Title: Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids
doi: 10.1016/j.cell.2018.07.009
Figure Lengend Snippet: Key Resources Table
Article Snippet:
Techniques: Control, Recombinant, Membrane, Cell Culture, Clinical Proteomics, Cell Recovery, Staining, Caspase-3 Assay, Software
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: Transient cytokine stimulation in tongue tissue and by spleen cells of premalignant oral lesion-bearing mice treated with programmed cell death (PD)-1 antibody. Mice with carcinogen-induced premalignant oral lesions were sacrificed after 1, 3 and 5 weeks of treatment with isotype control antibodies (Cont.) or PD-1 antibodies (αPD-1). Levels of cytokines interleukin (IL)-2, interferon (IFN)-γ, IL-6, IL-17, and IL-10 in tongue tissue and levels secreted by spleen cells were compared among the treatment groups. Shown are levels of cytokines (mean ± standard error of the mean [SEM]).
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques:
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: Treatment of premalignant lesion-bearing mice with PD-1 antibody tempers their lymph node cell secretion of most cytokines, except for IFN-γ. Mice with 4NQO-induced premalignant oral lesions were sacrificed after 1, 3 and 5 weeks of treatment with isotype control antibodies or PD-1 antibodies (αPD-1) and secretion of cytokines by their lymph node cells was compared. Shown are levels of secreted cytokines (mean ± SEM).
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques:
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: Increase in IFN-γ expression by CD4 + lymph node cells from mice bearing premalignant oral lesions after 5 weeks of PD-1 antibody treatment. Mice bearing 4NQO-induced premalignant oral lesions were treated with isotype control antibodies or PD-1 antibodies (αPD-1). After 1, 3 and 5 weeks, groups of mice were sacrificed and their spleens were immunostained extracellularly for CD4 or CD8 and intracellularly for IFN-γ. Shown are percentages of positive-staining cells (mean ± SEM).
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques: Expressing, Staining
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: PD-1 antibody treatment of mice bearing premalignant oral lesions transiently increases lymph node cell IFN-γ responses to a challenge of lysates of premalignant lesion or head and neck squamous cell carcinoma (HNSCC) tongue tissues, but not IL-17 or tumor necrosis factor (TNF)-α responses. Mice bearing 4NQO-induced premalignant oral lesions were treated with either isotype control antibodies or PD-1 antibodies (αPD-1). After 1, 3 and 5 weeks, groups of mice were sacrificed and their lymph node cells were cultured with lysates of control tongue tissues or lysates of premalignant lesion or HNSCC tongue tissues. Shown are levels of secreted cytokines by lymph node cells (mean ± SEM). * = p < 0.05; ** = p < 0.02; *** = p < 0.01.
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques: Cell Culture
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: PD-1 antibody treatment of mice bearing premalignant oral lesions transiently increases expression of IFN-γ by lymph node CD4 + cells in response to a challenge of lysates of premalignant lesion or HNSCC tongue tissues. Mice bearing 4NQO-induced premalignant oral lesions were treated with either isotype control antibodies or PD-1 antibodies (αPD-1). After 1, 3 and 5 weeks of treatment, sample mice were sacrificed and their lymph node cells (LN) were cultured with lysates of control normal tongue tissue (norm.) or lysates of premalignant lesion (premalig.) or HNSCC tongue tissues. Cultures were then immunostained for CD4 and IFN-γ. Shown are representative fluorescent dot-blots of spleen cells from mice treated with isotype control or anti-PD-1 antibodies.
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques: Expressing, Cell Culture
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: PD-1 antibody treatment of mice bearing premalignant oral lesions transiently increases expression of IFN-γ by lymph node CD4 + cells in response to a challenge of lysates of premalignant lesion or HNSCC tongue tissues. Mice bearing 4NQO-induced premalignant oral lesions were treated with either isotype control antibodies or PD-1 antibodies (αPD-1). After 1, 3 and 5 weeks of treatment, sample mice were sacrificed and their lymph node cells were cultured with lysates of control normal tongue tissue or lysates of premalignant lesion or HNSCC tongue tissues. Cultures were then immunostained for CD4 and IFN-γ. Shown are percentages of positive-staining cells (mean ± SEM). * = p < 0.05; ** = p < 0.02; *** = p < 0.01.
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques: Expressing, Cell Culture, Staining
Journal: Cancers
Article Title: Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment
doi: 10.3390/cancers9060062
Figure Lengend Snippet: Transient clinical response of mice bearing premalignant oral lesions to treatment with PD-1 antibodies. Mice with premalignant oral lesions were divided into groups of 15 mice each and initiated on treatment with isotype control antibodies or PD-1 antibodies (αPD-1). Progression of lesions toward cancer development was monitored by endoscopic examination of the oral cavity. These endoscopic images were quantitated in a blinded manner by counting the number of visible lesions, and giving lesions a gross pathologic score between 1 and 4 based on their horizontal and vertical size, and overall appearance. The following criteria were used for scoring: 1: flat macule, 2: raised papule, 3: raised plaque, 4: grossly exophytic. Shown are means ± SEM of clinical analyses.
Article Snippet: Treatment with IgG1 isotype control antibodies or
Techniques:
Journal: PLoS ONE
Article Title: Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs
doi: 10.1371/journal.pone.0092934
Figure Lengend Snippet: Bregs or non-Bregs B cells were co-cultured for 72 hours with VPD450-labeled FACS-purified CD4 + T cells, activated using Anti-Biotin MACSiBead (Miltenyi, T Cell Activation/Expansion Kit) and IL-2 (2 U/ml) and proliferation of CD4+ T cells determined by flow cytometry. ( a ) Right panel, shows a representative overlay and right panel depicts compilation of results, whereby the reduction in proliferation is normalized to CD4 + T cell proliferation alone (n = 4). ( b ) In antibody blocking experiments, labeled and activated CD4+ T cells were co-cultured with Bregs and under conditions shown above the representative histograms (n = 4) (α-IL-10 = IL-10R blocking antibody (20 ug/ml, Biolegend), α-PD-1 = PD-1 blocking antibody (10 ug/ml, Biolegend).
Article Snippet: To determine the effect of PD-L1/PD-1 and IL-10/IL-10R interactions in Breg-mediated inhibition of CD4+ T cell proliferation, VPD450-labeled FACS-purified CD4 + T cells were activated using Anti-Biotin MACSiBead loaded CD2, CD3, and CD28 antibodies (Miltenyi, T Cell Activation/Expansion Kit) and IL-2 (20U, NIH AIDS repository), cultured with medium alone, with Bregs, with Bregs and IL-10R blocking antibody (20 ug/ml, BD Pharmingen), with Bregs and
Techniques: Cell Culture, Labeling, Purification, Activation Assay, Flow Cytometry, Blocking Assay